Carlsberg to buy Britvic for 1,315p per share Carlsberg will also buy out Marston's from brewing joint venture Danish brewer plans to create integrated beverage business in UK Shares in Carlsberg, Britvic, Marston's all rise July 8 (Reuters) - Carlsberg (CARLb.CO), opens new tab has agreed to buy British soft drinks maker Britvic (BVIC.L), opens new tab for 3.3 billion pounds ($4.23 billion), a move the Danish brewer said would forge a UK beverage "powerhouse" and that sent both companies' shares higher. Carlsberg clinched the takeover with a sweetened bid of 1,315 pence per share - comprising cash and a special dividend of 25 pence a share - after the British company rejected 1,250 pence per share last month. The acquisition will create value for shareholders, contribute to growth and forge a combined beer and soft drink company that is unique in the UK, CEO Jacob Aarup-Andersen told investors on a conference call. "With this transaction we are creating a UK powerhouse," he said. He brushed off concerns from some analysts about integration risks, saying Carlsberg has a strong track record of running beer and soft drink businesses in several markets. Soft drinks already make up 16% of Carlsberg's volumes. COST SAVINGS As drinkers in some markets ditch beer for spirits or cut back on drinking altogether, brewers have looked to broaden their portfolio into new categories like hard seltzer, canned cocktails and cider, as well as zero-alcohol brews. Britvic sells non-alcoholic drinks in Britain, Ireland, Brazil and other international markets such as France, the Middle East and Asia. Carlsberg said the deal will deliver a number of benefits, including cost and efficiency savings worth 100 million pounds ($128 million) over five years as it takes advantage of common procurement, production and distribution networks. It will also see Carlsberg take over Britvic's bottling agreement with PepsiCo (PEP.O), opens new tab. Carlsberg already bottles PepsiCo drinks in several markets and there is scope to add more geographies in future, Aarup-Andersen said. arlsberg halted share buy backs on Monday as a result of the deal. Chief financial officer Ulrica Fearn said these would resume once Carlsberg reaches its revised target for net debt of 2.5 times EBITDA, from 3.5 times currently - a goal it expects to meet in 2027. "Whilst this represents a shift in the strategy away from organic top- and bottom-line growth and consistent returns to shareholders, we view it as a relatively low risk transaction with attractive financials," Jefferies analysts said in a note. Carlsberg also said on Monday it will buy out UK pub group Marston's (MARS.L), opens new tab from a joint venture for 206 million pounds. That will give it full ownership of the newly formed Carlsberg Britvic after the deal. ($1 = 0.7805 pounds) Get the latest news and expert analysis about the state of the global economy with Reuters Econ World. Sign up here. Reporting by Stine Jacobsen, Yadarisa Shabong and Emma Rumney Editing by Sherry Jacob-Phillips, Rashmi Aich, David Goodman and David Evans

Koenigsegg Agera RS Chimera combines technologies from Agera RS, CC850, and Jesko. An Agera RS platform features the engine from the Jesko and the simulated manual gearbox from the CC850. Development took three years, thanks to software and hardware integration challenges. A "chimera," for the uninitiated, is described as a mythical creature whose anatomy comes from multiple animals, creating a hybrid of two or more creatures' best bits. It's also the name of the latest one-off creation from Koenigsegg, and it's certainly apt; the Koenigsegg Agera RS Chimera is an amalgam of technologies from the decade-old, record-breaking Agera RS, the fascinatingly innovative CC850, and the awe-inspiring Jesko - which just recently set four new acceleration records. There's also a hint of Regera in here, which had some impressive records of its own. As reported by Mr. JWW, the strictly one-off special edition was commissioned by FIA President Mohammed Ben Sulayem, and both he and one of Koenigsegg's engineers arrived at the same name. Let's take a closer look and see exactly why this is a hybrid, even though it's not electrified. Three Cars In One The Chimera was originally a regular Agera RS and one of several Koenigsegg megacars owned by Ben Sulayem, but he asked Christian and the team to initiate a special project on his behalf. Around the same time, the extraordinary Koenigsegg CC850 was revealed at Monterey Car Week 2022, introducing the innovative Engage Shift System (ESS). This was based on the already astonishingly fast nine-speed Light Speed Transmission, with new actuators and sensors added to enable the simulation of a manual transmission without a physical link between the shifter and the gearbox. Like the rest of the world, the FIA boss was enamored by this novel technology, and as a wealthy 'Egg collector, he asked for it to be put into his special Agera-based project. Christian pondered this and ultimately decided to fulfill the request, in the process turning Ben Sulayem's special edition into something of a development mule for the ESS. But unlike the CC850, the Chimera got the larger turbos of the Jesko, enabling around 1,280 horsepower on regular gas and up to 1,600 hp on E85. That means this is an Agera RS with a CC850 transmission and a Jesko engine. On paper, that sounds simple, but the reality was anything but... Three Shifting Experiences Took Three Years To Combine According to a video from YouTuber and Koenigsegg distributor Mr. JWW, this development process took three years and required the relocation of the battery, new mounts for the powertrain, new harnesses, new software and controllers, and even a new infotainment system. To ensure all the electronics worked seamlessly was a challenge, but then Ben Sulayem asked for another layer of intricacy, requesting that paddle shifters be added, like in the Jesko Absolut and Jesko Attack. In the CC850, you could only switch between the simulated manual mode and fully automatic shifts, but now, the Chimera's development has unlocked manually operable paddles, which have now been added as the only option you can add to a CC850. There was also significant relocation and redesigning of suspension components, with parts from the Jesko and the Regera forming the subframe and elements of the suspension, respectively. A new scoop for the new transmission's cooler was also added, but it looks like it was always planned. Christian von Koenigsegg says this is a true one-off, saying that it would be cheaper and easier to start something all-new from scratch than to mix new and old technologies again, and that it's simply "too much work" to tackle a retrofit project. The Chimera is not completed just yet, as there are still subtle elements to refine, such as the bite point of the clutch pedal, but these minor issues will surely be resolved soon. It's an amazing feat, combining three hypercars in one, and we can't even fathom how Koenigsegg will top this in the future, but we don't doubt that Christian and his team will continue to do just that.

The world's first portable electrocardiograph was an 85-pound backpack, and now a 10-gram patch attached to your chest can transmit electrocardiograms uninterrupted for two weeks. The Apple Watch, which is worn by an estimated 100 million people, can send a text message to alert people when their heartbeat is irregular. Wearable sensors on the arms, wrists and fingers can now report arrhythmias, blood sugar levels, blood oxygen and other health indicators. Medical journals have also proposed a more ambitious vision - wearable devices can monitor patients with chronic diseases, eliminating the need for frequent hospital visits. They can spot potential health problems before a stroke or diabetes develops. The forces of health technology and wearables are converging. Tech giants like Apple (AAPL) and Alphabet's (GOOGL) Google are adding health features to their products. Medical technologists like electrocardiogram patch maker iRhythm Technologies or blood sugar monitor makers DexCom (DXCM) and Abbott Laboratories (ABT) are taking their devices beyond the clinic. "In the sensor world, people started on the consumer side and wanted to get into health care," said Kevin Sayer, chief executive of Decon Medical. "In health care, we're trying to be more consumer oriented, and I think all of those things are sort of colliding." Early bets favored the tech giants, with every health-related announcement from Apple, Google or Samsung Electronics hitting medical tech stocks. But changing doctors' practices will also require sustained investment in clinical trials. Big tech companies have cut back on investments in health care. Now it seems that medical technologists will be at the vanguard of the digital health revolution - with smartwatches and smart rings bringing them more customers who need to be diagnosed. Blake Goodner, co-founder of Bridger Management, a hedge fund focused on health care, said: "A group of medtech companies focused on digital health are maturing and reaching a scale where they can not only be profitable but also make investments to compete with larger tech companies." Tech giants aren't getting out of the health business. Apple's smartwatch has an electronic heart rate sensor that generates a single-point electrocardiogram, a wrist temperature sensor, and an accelerometer that can detect violent falls. Hundreds of millions of people are wearing smartwatches with health features from Apple or its rivals Samsung and Garmin.

Recently, according to the FT, citing the latest forecast data of the market research institute SemiAnalysis, AI chip giant NVIDIA will ship more than 1 million new NVIDIA H20 acceleration chips to the Chinese market this year, and it is expected that the cost of each chip is between $12,000 and $13,000. This is expected to generate more than $12 billion in revenue for Nvidia. Affected by the United States export control policy, Nvidia's advanced AI chip exports to China have been restricted, H20 is Nvidia based on H100 specifically for the Chinese market to launch the three "castration version" GPU among the strongest performance, but its AI performance is only less than 15% of H100, some performance is even less than the domestic Ascend 910B. When Nvidia launched the new H20 in the spring of this year, there were reports that due to the large castration of H20 performance, coupled with the high price, Chinese customers' interest in buying is insufficient, and they will turn more to choose China's domestic AI chips. Then there are rumors that Nvidia has lowered the price of the H20 in order to improve its competitiveness. However, the latest news shows that due to supply issues caused by the low yield of the Ascend 910B chip, Chinese manufacturers in the absence of supply and other better options, Nvidia H20 has started to attract new purchases from Chinese tech giants such as Baidu, Alibaba, Tencent and Bytedance. Analysts at both Morgan Stanley and SemiAnalysis said the H20 chip is now being shipped in bulk and is popular with Chinese customers, despite its performance degradation compared to chips Nvidia sells in the United States.

On the afternoon of July 8, local time, the Vietnamese Ministry of Health issued a notice stating that an 18-year-old girl in the country died of diphtheria. The Ministry of Health asked Nghe An Province and Bac Giang Province to take urgent action to control the epidemic. Diphtheria is an acute respiratory infectious disease caused by Corynebacterium diphtheriae, which is mainly transmitted through droplets and can also be indirectly transmitted by contact with objects containing Corynebacterium diphtheriae. Severe cases may show symptoms of poisoning throughout the body, complicated by myocarditis and peripheral nerve paralysis.